The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
This article was originally published in RPM Report
Executive Summary
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
You may also be interested in...
Kaiser Pushes Back on REMS: Acorda Listens; Will FDA?
Kaiser recognizes that some sponsors are trying to use REMS to make an end-run around gatekeepers, and it is fighting back. The non-profit integrated care system wants FDA to help, filing a citizen petition that could profoundly affect commercialization of new products in the US. The recently approved MS drug Ampyra offers a case-in-point.
Kaiser Pushes Back on REMS: Acorda Listens; Will FDA?
Kaiser recognizes that some sponsors are trying to use REMS to make an end-run around gatekeepers, and it is fighting back. The non-profit integrated care system wants FDA to help, filing a citizen petition that could profoundly affect commercialization of new products in the US. The recently approved MS drug Ampyra offers a case-in-point.
Orphan Drugs Plus REMS: A Perfect Fit?
Biopharma companies have a decidedly mixed view of FDA's new post-marketing safety authorities. But for one industry segment-companies concentrating in serving very small patient populations suffering from rare diseases-the new regulatory model is decidedly good for business. What does that mean for the future of Big Pharma?